Atormac
Neurology India
menu-bar5 Open access journal indexed with Index Medicus
  Users online: 3077  
 Home | Login 
About Editorial board Articlesmenu-bullet NSI Publicationsmenu-bullet Search Instructions Online Submission Subscribe Videos Etcetera Contact
  Navigate Here 
 »   Next article
 »   Previous article
 »   Table of Contents

 Resource Links
 »   Similar in PUBMED
 »  Search Pubmed for
 »  Search in Google Scholar for
 »Related articles
 »   Citation Manager
 »   Access Statistics
 »   Reader Comments
 »   Email Alert *
 »   Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed5956    
    Printed162    
    Emailed6    
    PDF Downloaded212    
    Comments [Add]    
    Cited by others 7    

Recommend this journal

 

 
Year : 2000  |  Volume : 48  |  Issue : 3  |  Page : 239--42

P300 in newly diagnosed non-dementing Parkinson's disease : effect of dopaminergic drugs.


Department of Neurology, Postgraduate Institute of Medical Education and Research, Chandigarh, 160012, India., India

Correspondence Address:
S Prabhakar
Department of Neurology, Postgraduate Institute of Medical Education and Research, Chandigarh, 160012, India.
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


PMID: 11025627

Rights and PermissionsRights and Permissions

Changes in cognitive function are an integral part of the clinical presentation of Parkinson's Disease (PD). P300 potential studies in early stages of Parkinson's disease are lacking and effect of L-dopa therapy on these potentials is controversial. In this study, changes in P300 potentials in early stages of PD and effects of dopaminergic therapy were investigated. P300 waves were elicited by standard auditory 'odd ball' paradigm and were recorded before the start of therapy and 15 days, 3 and 6 months after the start of L-dopa therapy in 25 newly diagnosed patients with idiopathic PD. All patients were classified according to Hoehn and Yahr scale. Minimental status examination (MMSE) was done in all. Control group had 20 normal subjects. The P300 latency was not significantly increased in early Parkinson's disease. This latency was reduced with dopaminergic therapy on 15th day, but increased later. Implications of the data are discussed.






[FULL TEXT] [PDF]*


        
Print this article     Email this article

Online since 20th March '04
Published by Wolters Kluwer - Medknow